Last reviewed · How we verify
UMC119-06
At a glance
| Generic name | UMC119-06 |
|---|---|
| Sponsor | Meridigen Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mesenchymal Stem Cells for Frailty Syndrome (PHASE1, PHASE2)
- Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells (PHASE2)
- Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) (PHASE1)
- Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). (PHASE1)
- Mesenchymal Stem Cells for The Treatment of Frailty Syndrome (PHASE1)
- Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease (PHASE1)
- Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMC119-06 CI brief — competitive landscape report
- UMC119-06 updates RSS · CI watch RSS
- Meridigen Biotech Co., Ltd. portfolio CI